Insider Selling: Intersect ENT Inc (XENT) CFO Sells $385,759.98 in Stock
Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $30.06, for a total transaction of $385,759.98. Following the transaction, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $836,659.98. The sale was disclosed in a document filed with the SEC, which is available through this link.
Intersect ENT Inc (NASDAQ XENT) opened at $29.92 on Friday. Intersect ENT Inc has a fifty-two week low of $10.50 and a fifty-two week high of $33.25.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The business had revenue of $22.31 million during the quarter, compared to analyst estimates of $21.53 million. During the same period in the previous year, the business posted ($0.22) EPS. The company’s quarterly revenue was up 20.8% on a year-over-year basis. equities research analysts forecast that Intersect ENT Inc will post -0.63 earnings per share for the current fiscal year.
Several research analysts have weighed in on the stock. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities reissued a “hold” rating and set a $25.00 price objective on shares of Intersect ENT in a report on Friday, November 3rd. Zacks Investment Research lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Canaccord Genuity raised their price objective on shares of Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Wednesday, September 13th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.43.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/08/insider-selling-intersect-ent-inc-xent-cfo-sells-385759-98-in-stock.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Stock Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related stocks with our FREE daily email newsletter.